you are here: HomeNewsWorld

Hydroxychloroquine combination risky for cancer patients with COVID-19: Study

The preliminary results suggest doctors may want to refrain from prescribing the decades-old malaria treatment hydroxychloroquine with the antibiotic azithromycin for these patients until more study is done, researchers said.

May 29, 2020 / 07:51 AM IST
Representative image

Representative image

Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on Thursday.

The preliminary results suggest doctors may want to refrain from prescribing the decades-old malaria treatment hydroxychloroquine with the antibiotic azithromycin for these patients until more study is done, researchers said.

"Treatment with hydroxychloroquine and azithromycin were strongly associated with increased risk of death," Dr. Howard Burris, president of the American Society of Clinical Oncology(ASCO), said in a briefing with reporters on the results.

The drug combination initially was thought to help COVID-19 patients, but recent data has cast doubt on the regimen.

The preliminary findings, to be presented this week at ASCO's virtual scientific meeting, show that the combination may pose a significant risk to cancer patients.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"Taking the combination gives a three times increased risk of dying within 30 days of any cause," Dr. Jeremy Warner of Vanderbilt University Medical System told reporters.

Trump, who has often promoted hydroxychloroquine, in a March 21 tweet called the combination potentially "one of the biggest game changers in the history of medicine."

That was based on a study of fewer than 40 patients in the International Journal of Antimicrobial Agents. More recent studies have shown little or no benefit and increased risks.

Warner and colleagues analyzed data on 925 patients with cancer who became infected with the coronavirus between March and April. Thirteen percent of the patients died within 30 days of their diagnosis.

Overall, patients whose cancers were actively progressing at the time of infection were five times more likely to die within 30 days than those who were in remission or had no current evidence of cancer.

In the trial, 180 patients were taking hydroxychloroquine in combination with azithromycin, and 90 were taking hydroxychloroquine alone.

The U.S. Food and Drug Administration has allowed healthcare providers to prescribe the drugs for COVID-19 through an emergency-use authorization, but has not approved the treatment.

The governments of France, Italy and Belgium moved on Wednesday to halt the use of hydroxychloroquine for COVID-19 patients following a World Health Organization decision on Monday to pause a large trial of the drug due to safety concerns.

Warner said hydroxychloroquine alone was not a significant risk factor when adjusting for other risks, noting that the number of individuals taking the drug alone was relatively small.

He said carefully designed trials are needed to clarify the risks and benefits of these drugs alone or in combination.

Nevertheless, Warner said his findings were largely consistent with a retrospective analysis published last week in the Lancet medical journal that looked at more than 96,000 people hospitalized with COVID-19. That study found that hydroxychloroquine was associated with an increased risk of death and heart rhythm problems. [nL4N2D43NN]

ASCO Chief Medical Officer Dr. Richard Schilsky said there is "insufficient evidence to support the routine use of hydroxychloroquine" to treat COVID-19 in patients who also have cancer, and urged caution until more data becomes available.

Schilsky said the treatment should only be used in the context of a clinical trial, per FDA guidance. Only two of the patients in the study were taking the drug as part of a clinical trial.

"This certainly will put a degree of caution for combining those two drugs in a cancer patient receiving therapy against COVID-19," said Dr. William Cance, chief scientific officer of the American Cancer Society.
Reuters
first published: May 29, 2020 07:36 am

stay updated

Get Daily News on your Browser
Sections